LFM-A13isapotentandselectiveinhibitorofBruton"styrosinekinase(BTK).LFM-A13maybeusefulasanewclassofchemosensitizingandapoptosis-promotingantileukemicagentsfortreatmentofpatientswithchemotherapy-resistantB-lineageleukemiasorlymphomas.MedKooCat#:401531Name:LFM-A13CAS#:244240-24-2ChemicalFormula:C11H8Br2N2O2ExactMass:357.89525MolecularWeight:360.0ElementalAnalysis:C,36.70;H,2.24;Br,44.39;N,7.78;O,8.89Synonym:LFMA13;LFM-A13;LFMA13IUPAC/ChemicalName:2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamideInChiKey:UVSVTDVJQAJIFG-VURMDHGXSA-NInChiCode:InChI=1S/C11H8Br2N2O2/c1-6(16)8(5-14)11(17)15-10-4-7(12)2-3-9(10)13/h2-4,16H,1H3,(H,15,17)/b8-6-SMILESCode:C/C(O)=C(C#N)/C(NC1=CC(Br)=CC=C1Br)=OTechnicalDataAppearance:SolidpowderPurity:>98%ShippingCondition:Shippedunderambienttemperatureasnon-hazardouschemical.ThisproductisstableenoughforafewweeksduringordinaryshippingandtimespentinCustoms.StorageCondition:Dry,darkandat0-4Cforshortterm(daystoweeks)or-20Cforlongterm(monthstoyears).Solubility:SolubleinDMSO,notinwaterShelfLife:>5yearsifstoredproperlyDrugFormulation:ThisdrugmaybeformulatedinDMSOStockSolutionStorage:0-4Cforshortterm(daystoweeks),or-20Cforlongterm(months).HarmonizedSystemCode:293490AdditionalInformation     References1:UckunF,DibirdikI,SarkissianA,QaziS.InvitroandinvivochemosensitizingactivityofLFM-A13,adual-functioninhibitorofBruton'styrosinekinaseandpolo-likekinases,againsthumanleukemicB-cellprecursors.Arzneimittelforschung.2011;61(4):252-9.doi:10.1055/s-0031-1296196.PubMedPMID:21650085.2:UckunFM.Chemosensitizinganti-canceractivityofLFM-A13,aleflunomidemetaboliteanalogtargetingpolo-likekinases.CellCycle.2007Dec15;6(24):3021-6.Epub2007Sep26.PubMedPMID:18073537.3:DuMezD,VenkatachalamTK,UckunFM.Large-scalesynthesisofGMPgradealpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)propenamide(LFM-A13),anewanti-cancerdrugcandidate.Arzneimittelforschung.2007;57(3):155-63.PubMedPMID:17469650.4:UckunFM,TibblesH,VenkatachalamT,DuMezD,ErbeckD.PreclinicaltoxicityandpharmacokineticsoftheBruton'styrosinekinase-targetinganti-leukemicdrugcandidate,alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)propenamide(LFM-A13).Arzneimittelforschung.2007;57(1):31-46.PubMedPMID:17341007.5:UckunFM,DibirdikI,QaziS,VassilevA,MaH,MaoC,BenyumovA,EmamiKH.Anti-breastcanceractivityofLFM-A13,apotentinhibitorofPolo-likekinase(PLK).BioorgMedChem.2007Jan15;15(2):800-14.Epub2006Oct26.PubMedPMID:17098432.6:TibblesHE,SamuelP,ErbeckD,MahajanS,UckunFM.Invivotoxicityandantithromboticprofileoftheoralformulationoftheantileukemicagent,LFM-A13-F.Arzneimittelforschung.2004;54(6):330-9.PubMedPMID:15281619.7:vandenAkkerE,vanDijkTB,SchmidtU,FelidaL,BeugH,LöwenbergB,vonLindernM.TheBtkinhibitorLFM-A13isapotentinhibitorofJak2kinaseactivity.BiolChem.2004May;385(5):409-13.PubMedPMID:15196000.8:UckunFM,VassilevA,BartellS,ZhengY,MahajanS,TibblesHE.Theanti-leukemicBruton'styrosinekinaseinhibitoralpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)propenamide(LFM-A13)preventsfatalthromboembolism.LeukLymphoma.2003Sep;44(9):1569-77.PubMedPMID:14565661.9:GilbertC,LevasseurS,DesaulniersP,DusseaultAA,ThibaultN,BourgoinSG,NaccachePH.Chemotacticfactor-inducedrecruitmentandactivationofTecfamilykinasesinhumanneutrophils.II.EffectsofLFM-A13,aspecificBtkinhibitor.JImmunol.2003May15;170(10):5235-43.PubMedPMID:12734372.10:UckunFM,ZhengY,Cetkovic-CvrljeM,VassilevA,LisowskiE,WaurzyniakB,ChenH,CarpenterR,ChenCL.Invivopharmacokineticfeatures,toxicityprofile,andchemosensitizingactivityofalpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)propenamide(LFM-A13),anovelantileukemicagenttargetingBruton'styrosinekinase.ClinCancerRes.2002May;8(5):1224-33.PubMedPMID:12006542.11:MahajanS,GhoshS,SudbeckEA,ZhengY,DownsS,HupkeM,UckunFM.Rationaldesignandsynthesisofanovelanti-leukemicagenttargetingBruton'styrosinekinase(BTK),LFM-A13[alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)propenamide].JBiolChem.1999Apr2;274(14):9587-99.PubMedPMID:10092645.